BERKELEY, CA -- (MARKET WIRE) -- 10/12/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will webcast its 2011 Analyst & Investor Day on Thursday, October 27, 2011, from 8:00 - 11:00 a.m. Eastern Time.
Presentations and discussions by outside experts and the management team will focus on how Dynavax plans to translate the superior clinical results provided by HEPLISAV™, its investigational hepatitis B vaccine, to a commercial success. Dynavax will discuss its action plan, market opportunity, the regulatory landscape, the potential upside of a diabetic vaccination recommendation, and its TLR9-based approach that leverages the mechanism of action of natural immunity.
To access the live webcast and the subsequent archived audio recording of the presentation, please log on to Dynavax's website at http://investors.dynavax.com/newsevents.cfm.
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and superior protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.
Source: Dynavax Technologies
News Provided by Acquire Media